Lv4
660 积分 2025-08-25 加入
Treatment advances across the cervical cancer spectrum
10小时前
待确认
[Management of adverse effects of standard regimens for small cell lung cancer]
4天前
已关闭
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
12天前
已完结
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer
1个月前
已完结
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of DualERBB2Blockade in Patients WithERBB2-Positive Breast Cancer
1个月前
已完结
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
1个月前
已完结
Optimization of Quenching Temperature to Minimize the Micro Segregation Induced Banding Phenomena in Quenching and Partitioning (Q&P) Steels
1个月前
已完结
Dendrite structure and microhardness of as-cast 4Cr5MoSiV1 steel between different homogenisation processes
1个月前
已完结
Abstract RF1-02: Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/ trastuzumab plus pertuzumab, as neoadjuvant treatment for patients w/ HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
1个月前
已完结
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
1个月前
已完结
皖公网安备34019202002308